Lymphodepletion with chemotherapeutic agents or total body irradiation (TBI) before
adoptive transfer of tumor-specific T cells is a critical advancement in the treatment of …

Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like
receptor ligands - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …

In the 1890s, a New York surgeon named William Coley found that he could destroy tumors
by injecting patients with live streptococcal bacteria. Coley didn't know how the bacteria …

Abstract Background The TLR7/8 agonist 3M-052 and the TLR9 agonist CpG ODN both
trigger innate immune responses that support the induction of tumor-specific immunity …

The function of the Toll-like receptor (TLR) family members has been extensively studied in
the recent decades. The TLR family is generally involved in the defense against microbial …

Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological
adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved …

Abstract Toll-like receptors (TLRs), as the most important pattern recognition receptors in
innate immunity, play a pivotal role in inducing immune response through recognition of …

The immune system encompasses a broad array of defense mechanisms against foreign
threats, including invading pathogens and transformed neoplastic cells. Toll-like receptors …

Accumulating preclinical evidence indicates that Toll-like receptor (TLR) agonists efficiently
boost tumor-targeting immune responses (re) initiated by most, if not all, paradigms of …

The potentiation of immune responses to tumor-associated antigen (Ag) is a pivotal issue in
immunotherapy for cancer and thus requires the use of adjuvants, which are involved in …